Patents, Trade Marks, Designs, Copyrights, IP Solicitors, Appeals and Oppositions, Due Diligence and Strategy.

HGF offers everything you would expect of a world-class intellectual property firm, including patent and trade mark acquisition as well as appeals and oppositions to protect your creative work.

We also focus on providing a bespoke service tailored to your industry, to ensure you really get the most out of your big ideas. Our teams are dedicated to providing professional, expert advice and support every step of the way.

The latest news and cutting edge commentary from across the group

September 2017
September 2017

Oxford Bacteriophage Conference 2017

HGF Partner Craig Thomson will be Co-presenting "Creating Impact: The challenges and opportunities of commercialisation in the field of bacteriophage research" alongside Professor Martha RJ Clokie.

Find out more
September 2017

IP in Retail Conference 2017

IP in Retail 2017 - HGF's fifth annual conference will be held in September in Leeds and London. The conference addresses topical IP issues for retailers.

Find out more
August 2017
August 2017

Plausibility at the EPO - Decision T 0488/16 Dasatinib/BRISTOL-MYERS SQUIB

An inventive step requiring particular technical effect or solving a particular problem must have a plausible disclosure of having achieved that in the original specification.

Plausibility at the EPO - Decision T 0488/16 Dasatinib/BRISTOL-MYERS SQUIB Find out more
July 2017
July 2017

CpG Oligonucleotide Therapeutics - A History Lesson for CRISPR?

When we look at the emerging and likely future battles being fought to establish dominance in the emerging field of CRISPR technologies, it may be too easy to conclude that one has no frame of reference to help understand what the conclusion will likely be. However, as Harry S Truman said;…

CpG Oligonucleotide Therapeutics - A History Lesson for CRISPR? Find out more
July 2017

UK Patent Equivalents, Exclusions and Estoppel – where are we now?

A 5 year battle between Eli Lilly (Lilly) and Actavis centred on Lilly’s patent for the use of pemetrexed disodium for cancer therapy, has culminated in a decision from the UK Supreme Court, allowing Lilly’s appeal and deciding that Actavis' Products directly infringe Eli Lilly's patent in…

UK Patent Equivalents, Exclusions and Estoppel – where are we now? Find out more
July 2017

Crucial Rule Changes for the Patentability of Plants and Animals at the European Patent Office

Starting with immediate effect from the 1st July 2017, plants and animals obtained from essentially biological processes will no longer be patentable before the European Patent Office (EPO).

Crucial Rule Changes for the Patentability of Plants and Animals at the European Patent Office Find out more